時        間：114年7月26日(六) 13:15~17:00 (視訊)
地        點:   臺灣血液腫瘤藥學會YouTube頻道線上
主辦單位：臺灣血液腫瘤藥學會
協辦單位：中化裕民健康事業股份有限公司、嬌生股份有限公司

注意事項：
1.本研討會採用GOOGLE簽到，須完成簽到、課後滿意度及簽退，方能獲得學分。
2.報名開始日：即日起至7月26日
3.若有相關課程問題，請洽研討會聯絡人任冠臻小姐。E-mail: twhopa@gmail.com


---請使用海報連結掃碼填單報名---

Bispecific Antibodies in R/R FL and R/R DLBCL
Aligning on Clinical Best Practices

CME/CNE/CPE

Chicago Hilton
Sunday, June 1, 2025 | 6:45 PM - 8:15 PM CT

Join us for an enlightening 90-minute live symposium designed exclusively for hematologists and oncologists treating relapsed/refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL). As the landscape evolves, staying abreast of innovative therapies is crucial for optimizing patient outcomes.

This symposium offers a unique opportunity to engage with leading experts in the field, gain insights from clinical trial data, and explore practical applications of bispecific antibody therapy in your practice.
   

Improve the integration of immunotherapy strategies in gastroesophageal cancer.
Education Alert
Decoding PD-L1 Scoring: Guiding Immunotherapy for Gastroesophageal Cancers
45 min EBAC
Apply appropriate PD-L1 testing methods to inform immunotherapy strategies for gastroesophageal cancer.

Jason Efstathiou, MD, PhD; Brandon Mancini, MD, MBA, FACRO; Comron Hassanzadeh, MD, MPH; and Bridget Koontz, MD, FASTRO, discuss the evolving role of PSMA PET imaging in prostate cancer, examining its impact on diagnosis, disease staging, treatment decisions, and posttreatment assessment. They also review key clinical trial data, current guideline recommendations, and real-world applications of PSMA PET imaging in practice.

Featured Video
 

FDA grants accelerated approval to the combination of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer On May 8, 2025, the Food and Drug Administration granted accelerated approval to the combination of avutometinib and defactinib (Avmapki Fakzynja Co-pack, Verastem, Inc.) for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. FDA approves belzutifan for pheochromocytoma or paraganglioma On May 14, 2025, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) for adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). This represents the first FDA approval of an oral therapy for PPGL. FDA grants accelerated approval to telisotuzumab vedotin-tllv for NSCLC with high c-Met protein overexpression On May 14, 2025, the Food and Drug Administration granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis, AbbVie Inc.), a c-Met-directed antibody and microtubule inhibitor conjugate, for adults with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [≥50% of tumor cells with strong (3+) staining], as determined by an FDA-approved test, who have received a prior systemic therapy. FDA approves retifanlimab-dlwr with carboplatin and paclitaxel and as a single agent for squamous cell carcinoma of the anal canal On May 15, 2025, the Food and Drug Administration approved retifanlimab-dlwr (Zynyz, Incyte Corporation) with carboplatin and paclitaxel for the first-line treatment of adults with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). The FDA also approved retifanlimab-dlwr, as a single agent, for adults with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy.

    Data from the POD1UM-303/InterAACT2 trial support the approval of retifanlimab/chemotherapy for patients with squamous cell carcinoma of the anal canal.